NYSE:AZNAstraZeneca Stock Price, Forecast & News

AstraZeneca's stock was trading at $44.58 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, AZN shares have increased by 23.9% and is now trading at $55.22. View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 2 sell ratings, 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for AstraZeneca.

AstraZeneca is scheduled to release its next quarterly earnings announcement on Thursday, July 23rd 2020. View our earnings forecast for AstraZeneca.

AstraZeneca plc (NYSE:AZN) released its quarterly earnings data on Wednesday, April, 29th. The company reported $0.53 earnings per share for the quarter, beating analysts' consensus estimates of $0.47 by $0.06. The company earned $6.35 billion during the quarter, compared to analysts' expectations of $5.95 billion. AstraZeneca had a return on equity of 33.97% and a net margin of 5.94%. The business's revenue was up 16.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.89 earnings per share. View AstraZeneca's earnings history.

AstraZeneca announced a semi-annual dividend on Tuesday, February 18th. Shareholders of record on Friday, February 28th will be paid a dividend of $0.95 per share on Monday, March 30th. This represents a dividend yield of 2.8%. The ex-dividend date is Thursday, February 27th. View AstraZeneca's dividend history.

AstraZeneca's stock split before market open on Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly issued shares were payable to shareholders after the closing bell on Friday, July 24th 2015. An investor that had 100 shares of AstraZeneca stock prior to the split would have 200 shares after the split.

8 equities research analysts have issued 1-year price objectives for AstraZeneca's stock. Their forecasts range from $55.00 to $60.00. On average, they anticipate AstraZeneca's stock price to reach $57.50 in the next twelve months. This suggests a possible upside of 4.1% from the stock's current price. View analysts' price targets for AstraZeneca.

News stories about AZN stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. AstraZeneca earned a media sentiment score of 1.5 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutAstraZeneca.

Some companies that are related to AstraZeneca include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Pfizer (PFE), Novartis (NVS), Merck & Co., Inc. (MRK), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Sanofi (SNY), GlaxoSmithKline (GSK), Commonwealth Bank of Australia (CSLLY), Celgene (CELG) and Vertex Pharmaceuticals (VRTX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include Pfizer (PFE), AbbVie (ABBV), AT&T (T), Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), NVIDIA (NVDA), Alibaba Group (BABA), Cisco Systems (CSCO), Bank of America (BAC) and Johnson & Johnson (JNJ).

AstraZeneca trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN."

AstraZeneca's stock is owned by many different retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (2.57%), Primecap Management Co. CA (2.16%), Jennison Associates LLC (1.48%), Capital International Investors (1.08%), Fisher Asset Management LLC (0.63%) and Invesco Ltd. (0.41%). View institutional ownership trends for AstraZeneca.

AZN stock was sold by a variety of institutional investors in the last quarter, including Primecap Management Co. CA, Russell Investments Group Ltd., Eaton Vance Management, Magnetar Financial LLC, Cookson Peirce & Co. Inc., Voloridge Investment Management LLC, Waddell & Reed Financial Inc., and Parametric Portfolio Associates LLC. View insider buying and selling activity for AstraZeneca.

AZN stock was acquired by a variety of institutional investors in the last quarter, including Capital International Investors, BlackRock Inc., Wellington Management Group LLP, Jennison Associates LLC, Invesco Ltd., Capital World Investors, Sphera Funds Management LTD., and Nuveen Asset Management LLC. View insider buying and selling activity for AstraZeneca.

Shares of AZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AZN stock can currently be purchased for approximately $55.22.

AstraZeneca has a market capitalization of $144.92 billion and generates $24.38 billion in revenue each year. The company earns $1.34 billion in net income (profit) each year or $1.75 on an earnings per share basis. AstraZeneca employs 64,400 workers across the globe.

The official website for AstraZeneca is www.astrazeneca.com.

AstraZeneca's mailing address is 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0, CB2 0AA. The company can be reached via phone at 44-20-3749-5000 or via email at [email protected]